The proposed $2.1bn acquisition of Endocyte Inc. by Novartis AG highlights the substantial opportunity for Telix in radiopharmaceuticals and prostate cancer in particular. Just one of a portfolio of clinical stage radiotherapy and radiotherapy programmes, Telix's TLX-591 promises a superior second generation product. With potentially better efficacy and tolerability compared to the Endocyte's lead product 177Lu-PSMA-617 currently in Phase III, the antibody-based TLX-591 has the potential for ear ....
18 Oct 2018
Novartis Endocyte move highlights opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Novartis Endocyte move highlights opportunity
Telix Pharmaceuticals Ltd. (TLX:ASX) | 0 0 0.0%
- Published:
18 Oct 2018 -
Author:
Chris Redhead -
Pages:
5
The proposed $2.1bn acquisition of Endocyte Inc. by Novartis AG highlights the substantial opportunity for Telix in radiopharmaceuticals and prostate cancer in particular. Just one of a portfolio of clinical stage radiotherapy and radiotherapy programmes, Telix's TLX-591 promises a superior second generation product. With potentially better efficacy and tolerability compared to the Endocyte's lead product 177Lu-PSMA-617 currently in Phase III, the antibody-based TLX-591 has the potential for ear ....